Navigation Links
Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
Date:6/13/2011

NEW YORK, June 13, 2011 /PRNewswire/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units – U.S. adult stem cells, China adult stem cells, and China pharmaceuticals, announced that its Suzhou Erye Pharmaceutical subsidiary ("Erye") has received approval from the State Food and Drug Administration (SFDA) in China for its sixth major production line which is responsible for the production of over 20 finished pharmaceutical products, 80% of which are on the National Insurance Drug List. The combined production lines now certified by the SFDA are six of eight planned and were responsible for approximately 99% of Erye’s 2010 revenues. In 2010, Erye reported full year sales of close to $70 million, generating approximately $10 million in earnings. Erye reported sales of over $18 million for Q1-2011. This represents an increase of 15% versus the same period a year ago and 43% versus the same period two years ago. More importantly, the capacity constraints associated with Erye operating out of its former facility have been removed.

NeoStem's Chairman and CEO, Dr. Robin L. Smith, commented, “The Chinese pharmaceutical market, which is the third largest in the world, has estimated sales of over $50 billion for 2011, and is expected to double in the next five years. This significant forecasted growth was an important consideration in our agreeing to reinvest our dividends into the company to support the relocation so that Suzhou Erye can be positioned to capture this growth and maximize the value of NeoStem’s 51% interest in Suzhou Erye. Based on the capacity of the new facility, and anticipated volume growth, Erye’s top line revenues should see solid growth in the years ahe
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
2. Reduced Lung Capacity Accelerates With Diabetes
3. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
4. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
5. Millstone Medical Outsourcing Opens New, Advanced Clean Room to Expand Capacity for Sterile Packaging
6. Safe Life Ramps Production Capacity of Comfortable, Breathable N95 Respirator Amid Worldwide Shortage
7. New Technology Center Increases B. Brauns Infusion Pump Capacity
8. NVHA and Inova Health System Utilize Philips VISICU eICU® Program to Increase Surge Capacity During All-Hazards Event
9. InspireMD Boosts MGuard Production Capacity
10. Anodizing Leader Expands Capacity at U.S. Facility
11. Millstone Medical Outsourcing Expands Sales, Marketing Capacity, Hires Two Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 BioElectronics Corp. (PINKSHEETS: BIEL), the ... announced that CEO, Andrew J. Whelan ... Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling ... the counter sales. "It,s been 37 ... classification schema," Whelan said.  "While the old classification ...
(Date:5/21/2013)... 2013  Janssen R&D Ireland (Janssen) today announced ... Phase 3 PROMISE study demonstrating that use of ... sustained virologic response 12 weeks after the end ... genotype 1 chronic hepatitis C adult patients with ... fibrosis, when administered once daily with pegylated interferon ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... Novocure, a commercial stage private oncology company, announced ... supply agreement with ITT Electronic Systems, a subsidiary ... (NYSE: ITT). ITT Electronic Systems supplies Novocure with ... disposable electrodes for the NovoTTF-100A System, an FDA ...
... American Pacific Corporation (NASDAQ: APFC ... its Fiscal 2011 third quarter financial results on Thursday, August ... and Chief Executive Officer and Dana Kelley, Vice President, Chief ... at 1:30 p.m. Pacific Time. Callers may listen ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3American Pacific to Release Financial Results and Hold Fiscal 2011 Third Quarter Investor Teleconference 2
(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...
(Date:5/21/2013)... 21, 2013 HealthSmart continues to grow ... presence has required the hiring of new talent in ... pleased to announce that Dawn Powell has joined the ... the Director of Account Management in the Central Region ... Irving, Texas. With extensive client management, employee benefits, and ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... Tips on What to Do Now as States Struggle,with ... Red Cross,chapters throughout the Midwest are keeping pace with ... landscape, despite several,chapter offices being closed due to the ... from home or using partnerships with,local government or community ...
... 11 AIDS Healthcare,Foundation (AHF) today blasted former ... for his stubbornness and,recent failure to apologize for ... in which he called for people living with,HIV/AIDS ... the time, Huckabee,told Associated Press in response to ...
... Sell Out Consumers with Unaffordable Mandate, SANTA MONICA, ... as much as 14% have led a state panel,to ... health plans. The vote,came less than a month before ... or pay penalties that increase monthly, and as,California politicians ...
... Calls on Every Candidate from Every Party to ... WASHINGTON, Dec. 11 AIDS Action released a,statement ... rewrite,his HIV/AIDS platform to ensure that the policies ... and end stigma against people,living with HIV. "Governor ...
... new study in Nature, Brandeis University Howard Hughes Medical ... curtain on the secret lives of enzymes, the ubiquitous ... a slew of sophisticated technologies to capture a key ... able to show that these proteins are not the ...
... bortezomib (Velcade) and two other drugs is showing a ... multiple myeloma, a team headed by Dana-Farber Cancer Institute ... Society of Hematology. , The three-pronged regimen of Velcade, ... has achieved an overall response rate of 98 ...
Cached Medicine News:Health News:Darkness and Cold Prevail in the Midwest 2Health News:Darkness and Cold Prevail in the Midwest 3Health News:Darkness and Cold Prevail in the Midwest 4Health News:Huckabee's Defense of Earlier, Alarmist AIDS Stance Shows Unsuitability for Presidency, Says AHF 2Health News:Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed 2Health News:AIDS Action Calls on Huckabee to Follow HIV/AIDS Science 2Health News:Caught in the act: The dynamic dance of enzymes 2Health News:3-drug combination 'extremely promising' as first-line therapy for multiple myeloma 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: